SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Keith J who wrote (31023)5/21/2008 2:23:56 PM
From: Paul Senior  Read Replies (2) of 78715
 
I assume it's patent expirations, and fear there are no replacement drugs to sustain revenue.

If I understand Warren Buffett's recent interview comments correctly, he doesn't understand the drug pipeline of SNY (stock he recently added to). Just that there IS a pipeline (research will be brought to market), and if that takes five years to happen and he has to hold that long for the perception of the stock to improve, that is okay with him. Since he is buying as ltb&h.

So I figure I might try the same with PFE. I don't see div. being cut - although it very well could be - it would be a drastic move though by management, I'd say. So I am buying with a view to hold also for several years for the better times, and meanwhile I collect a 6% div. yield.

I hold several of these giant pharma companies as a package. I have a few shares of SNY (am underwater with it), and I may add more SNY to follow Mr. Buffett.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News